The potential value of 5-androstenediol in countering acute radiation syndrome
Drug Discov Today. 2023 Dec 12:103856. doi: 10.1016/j.drudis.2023.103856. Online ahead of print.ABSTRACTModerate-to-high doses of ionizing irradiation can lead to potentially life-threatening morbidities and increase mortality risk. In preclinical testing, 5-androstenediol has been shown to be effective in protecting against hematopoietic acute radiation syndrome. This agent is important for innate immunity, serves to modulate cell cycle progression, reduces radiation-induced apoptosis, and regulates DNA repair. The drug has been evaluated clinically for its pharmacokinetics and safety. The United States Food and Drug Admi...
Source: Drug Discovery Today - December 14, 2023 Category: Drugs & Pharmacology Authors: Vijay K Singh Thomas M Seed Source Type: research
The potential value of 5-androstenediol in countering acute radiation syndrome
Drug Discov Today. 2023 Dec 12:103856. doi: 10.1016/j.drudis.2023.103856. Online ahead of print.ABSTRACTModerate-to-high doses of ionizing irradiation can lead to potentially life-threatening morbidities and increase mortality risk. In preclinical testing, 5-androstenediol has been shown to be effective in protecting against hematopoietic acute radiation syndrome. This agent is important for innate immunity, serves to modulate cell cycle progression, reduces radiation-induced apoptosis, and regulates DNA repair. The drug has been evaluated clinically for its pharmacokinetics and safety. The United States Food and Drug Admi...
Source: Drug Discovery Today - December 14, 2023 Category: Drugs & Pharmacology Authors: Vijay K Singh Thomas M Seed Source Type: research
The potential value of 5-androstenediol in countering acute radiation syndrome
Drug Discov Today. 2023 Dec 12:103856. doi: 10.1016/j.drudis.2023.103856. Online ahead of print.ABSTRACTModerate-to-high doses of ionizing irradiation can lead to potentially life-threatening morbidities and increase mortality risk. In preclinical testing, 5-androstenediol has been shown to be effective in protecting against hematopoietic acute radiation syndrome. This agent is important for innate immunity, serves to modulate cell cycle progression, reduces radiation-induced apoptosis, and regulates DNA repair. The drug has been evaluated clinically for its pharmacokinetics and safety. The United States Food and Drug Admi...
Source: Drug Discovery Today - December 14, 2023 Category: Drugs & Pharmacology Authors: Vijay K Singh Thomas M Seed Source Type: research
Use of suboptimal control arms in randomized clinical trials of investigational cancer drugs in China, 2016-2021: An observational study
CONCLUSIONS: In this study, over one-eighth of randomized trials of cancer drugs registered to apply for regulatory approval in China used a suboptimal comparator. Our results highlight the necessity to refine the design of randomized trials to generate optimal clinical evidence for new cancer therapies.PMID:38085706 | DOI:10.1371/journal.pmed.1004319 (Source: Cancer Control)
Source: Cancer Control - December 12, 2023 Category: Cancer & Oncology Authors: Yichen Zhang Dingyi Chen Siyuan Cheng Zhizhou Liang Lu Yang Qian Li Lin Bai Huangqianyu Li Wei Liu Luwen Shi Xiaodong Guan Source Type: research
Synergistic effect of adavosertib and fimepinostat on acute myeloid leukemia cells by enhancing the induction of DNA damage
SummaryIn recent years, a number of novel pharmaceutical agents have received approval for the management of acute myeloid leukemia (AML). However, there is still ample opportunity for enhancing efficacy. The Wee1 inhibitor adavosertib (ADA) shows promise for the treatment of AML. Based on the effect of drugs on DNA damage, we conducted a combination study involving ADA and fimepinostat (CUDC-907), a dual inhibitor of PI3K and histone deacetylase (HDAC). We observed that the combination of CUDC-907 and ADA exhibited a synergistic effect in enhancing the antileukemic activity in both AML cell lines and primary patient sampl...
Source: Investigational New Drugs - December 12, 2023 Category: Drugs & Pharmacology Source Type: research
Use of suboptimal control arms in randomized clinical trials of investigational cancer drugs in China, 2016 –2021: An observational study
ConclusionsIn this study, over one-eighth of randomized trials of cancer drugs registered to apply for regulatory approval in China used a suboptimal comparator. Our results highlight the necessity to refine the design of randomized trials to generate optimal clinical evidence for new cancer therapies. (Source: PLoS Medicine)
Source: PLoS Medicine - December 12, 2023 Category: Internal Medicine Authors: Yichen Zhang Source Type: research
RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma
SummaryIdentifying biomarkers to evaluate the therapeutic effect of immune checkpoint inhibitors (ICIs) is crucial. Regulatory Associated Protein of MTOR Complex 1 (RPTOR), one of the genes in the mTOR pathway, plays a role in regulating tumor progression. However, the connection between RPTOR mutation and the efficacy of ICIs in melanoma remains unclear. The data of ICIs-treated melanoma patients in discovery (n = 384) and validation (n = 320) cohorts were obtained from cBioPortal databases. The genomic data in the two cohorts was used to investigate the connection between RPTOR mutation and immunotherapy efficac...
Source: Investigational New Drugs - December 10, 2023 Category: Drugs & Pharmacology Source Type: research
Clinical characteristics, diagnosis, treatment, and prognosis of nivolumab induced gastritis
SummaryGastritis has recently been reported to be associated with nivolumab, and the clinical characteristics of nivolumab induced gastritis remain unclear. To explore the clinical characteristics of nivolumab induced gastritis, and to provide reference for the classification and treatment guidelines of immune checkpoint inhibitors -related gastritis. Case reports, case series, and clinical studies of nivolumab induced gastritis were retrospectively analyzed by searching the database from the establishment of the database until September 30, 2023. Forty-seven were included, with a median age of 57 years (range 16, 93). T...
Source: Investigational New Drugs - December 8, 2023 Category: Drugs & Pharmacology Source Type: research
A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen. - PATROL-I-
SummaryDexamethasone is one of the key antiemetic agents and is widely used even now. However, dexamethasone has been associated with several adverse reactions even after short-term administration. Therefore, developing a steroid-free antiemetic regimen is an important issue to consider. Thus, the purpose of this study was to investigate the efficacy and safety of palonosetron, aprepitant, and olanzapine in a multi-institutional phase II study. Chemotherapy-naive patients scheduled to receive cisplatin were enrolled and evaluated for the occurrence of chemotherapy-induced nausea and vomiting during 120 h after chemothera...
Source: Investigational New Drugs - December 6, 2023 Category: Drugs & Pharmacology Source Type: research
Phase I/II trial of BMS-986,205 and nivolumab as first line therapy in hepatocellular carcinoma
ConclusionCombination BMS-986,205 and nivolumab showed a manageable safety profile with durable benefit as first-line therapy in a meaningful subset of advanced HCC patients. (Source: Investigational New Drugs)
Source: Investigational New Drugs - December 1, 2023 Category: Drugs & Pharmacology Source Type: research
Kilogram ‐Scale Synthesis of Extremely Small Gadolinium Oxide Nanoparticles as a T1‐Weighted Contrast Agent for Magnetic Resonance Imaging
In this study, polymaleic acid (PMA) is found to be an ideal stabilizer to synthesize ES-GdONs. Compared with ES-GdON-PAA, the PMA-stabilized ES-GdON (ES-GdON-PMA) has a lowerr2/r1 ratio (2.05, 7.0 T) and a lower blood circulation half-life (37.51 min). The optimized ES-GdON-PMA-9 has an exceedingly small particle size (2.1 nm), excellent water dispersibility, and stability. A facile, efficient, and environmental friendly synthetic method is developed for large-scale synthesis of the ES-GdONs-PMA. The weight of the optimized freeze–dried ES-GdON-PMA-26 synthesized in a 20 L of reactor reaches the kilogram level. The ...
Source: Small - November 21, 2023 Category: Nanotechnology Authors: Lihe Wu,
Xuanyi Lu,
Yudie Lu,
Meng Shi,
Shuai Guo,
Jie Feng,
Sugeun Yang,
Wei Xiong,
Yikai Xu,
Chenggong Yan,
Zheyu Shen Tags: Research Article Source Type: research
Molecular profiling and prognostic analysis in Chinese cholangiocarcinoma: an observational, retrospective single-center study
This study provides an overview of genetic alterations in Chinese patients with CCA, which will provide novel potential biomarkers for the diagnosis of CCA and may guide targeted therapeutic strategies for Chinese patients with CCA. (Source: Investigational New Drugs)
Source: Investigational New Drugs - November 17, 2023 Category: Drugs & Pharmacology Source Type: research
Immunoneoadjuvant therapy with immune checkpoint inhibitors of gastric cancer: an emerging exemplification
This article reviews the progress in the use of ICI monotherapy and in combination with alternative therapies for the treatment of gastric cancer to aid in the development of gastric cancer immunoneoadjuvant therapy and improve the overall therapeutic benefit. (Source: Investigational New Drugs)
Source: Investigational New Drugs - November 16, 2023 Category: Drugs & Pharmacology Source Type: research
Endosomal recycling inhibitors downregulate the androgen receptor and synergise with enzalutamide
SummaryProstate cancer is the second most frequent cancer diagnosed in men, and accounts for one-fifth of cancer associated deaths worldwide. Despite the availability of effective prostate cancer therapies, if it is not cured by radical local treatment, progression to drug resistant metastatic prostate cancer is inevitable. Therefore, new drugs and treatment regimens are urgently required to overcome resistance. We have recently published research demonstrating that targeting the endosomal recycling pathway, a membrane transport pathway that recycles internalised cell surface proteins back to the plasma membrane, may be a ...
Source: Investigational New Drugs - November 14, 2023 Category: Drugs & Pharmacology Source Type: research
Fecal Microbiota Transplantation: History, Procedure and Regulatory Considerations
Presse Med. 2023 Nov 7:104204. doi: 10.1016/j.lpm.2023.104204. Online ahead of print.ABSTRACTFecal microbiota transplantation (FMT) is a medical treatment which involves the transfer of feces from a healthy donor to a recipient to restore the balance of gut microbiota and improve clinical outcomes. FMT has gained recognition in recent years due to its effectiveness in treating recurrent Clostridioides difficile infections (rCDI) and other gastrointestinal disorders. Additionally, it has been studied as an intervention for some other conditions, like inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). This ...
Source: Presse Medicale - November 9, 2023 Category: General Medicine Authors: Thanush D M P Venkatesh Source Type: research
